Cargando…

Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy

We report a case of successful neoadjuvant four-drug combination therapy to avoid total pneumonectomy. A 33-year-old male patient was diagnosed with locally advanced non-squamous NSCLC harboring EGFR mutation in the left lower lobe. The patient experienced significant clinical downstaging after two...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jingpei, Xu, Ke, Cai, Weipeng, Zhang, Yalei, Zeng, Xin, Cui, Fei, Hao, Zhexue, Liu, Jun, He, Jianxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378529/ https://www.ncbi.nlm.nih.gov/pubmed/32766151 http://dx.doi.org/10.3389/fonc.2020.01145

Ejemplares similares

Erratum: Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
Publicado: (2020)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
por: Sun, Li, et al.
Publicado: (2021)

Video-assisted thoracoscopic surgery for primary lung cancer resections in patients with moderate to severe chronic obstructive pulmonary diseases
por: Xu, Ke, et al.
Publicado: (2021)

Morbidity and mortality after pneumonectomy in smokers with NSCLC
por: Kirschbaum, Andreas, et al.
Publicado: (2008)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

Andrographolide attenuates epithelial‐mesenchymal transition induced by TGF‐β1 in alveolar epithelial cells
por: Li, Jingpei, et al.
Publicado: (2020)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
por: Van De Stadt, Eveline, et al.
Publicado: (2022)

Evaluate the outcome of pneumonectomy for stage III a-N2 NSCLC
por: Park, Sungjoon, et al.
Publicado: (2015)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis
por: Li, Wenqian, et al.
Publicado: (2021)

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC
por: Peng, Weiwei, et al.
Publicado: (2023)

EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome
por: Yang, Hainan, et al.
Publicado: (2022)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
por: Ma, Li, et al.
Publicado: (2021)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021)

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
por: Shi, Xiaoshun, et al.
Publicado: (2021)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
por: Wang, Xiaomeng, et al.
Publicado: (2019)

High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases
por: Laganà, Marta, et al.
Publicado: (2020)

A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC
por: Chen, Wufei, et al.
Publicado: (2021)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
por: Pasello, Giulia, et al.
Publicado: (2022)

Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
por: Zhang, Baihua, et al.
Publicado: (2022)

Underutilization of Systemic Therapy in Patients With NSCLC Undergoing Pneumonectomy: A Missed Opportunity for Survival
por: Rodriguez-Quintero, Jorge Humberto, et al.
Publicado: (2023)

Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy
por: Kimura, Tomoki, et al.
Publicado: (2015)

The Polymorphism and Expression of EGFL7 and miR-126 Are Associated With NSCLC Susceptibility
por: Liu, Weipeng, et al.
Publicado: (2022)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wu, Qiang, et al.
Publicado: (2021)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China
por: Guan, Haijing, et al.
Publicado: (2022)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
por: Wang, Hongming, et al.
Publicado: (2023)

Case Report: A rare case of familial lung cancer requiring pneumonectomy in three male siblings
por: Kaprin, Andrey, et al.
Publicado: (2022)

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
por: Lin, Ruiting, et al.
Publicado: (2021)

COL8A1 Promotes NSCLC Progression Through IFIT1/IFIT3-Mediated EGFR Activation
por: Zan, Xiangyi, et al.
Publicado: (2022)

Effects of Preserving the Pulmonary Vagus Nerve Branches on Cough After Pneumonectomy During Video-Assisted Thoracic Surgery
por: Gu, Shaorui, et al.
Publicado: (2022)

Primary pneumonectomy, pneumonectomy after induction therapy, and salvage pneumonectomy: a comparison of surgical and prognostic outcomes
por: Sakakura, Noriaki, et al.
Publicado: (2020)

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series
por: Feng, Shao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6to4tfen8nukefr8cikhaarib9